Investors are reevaluating their outlook on Moderna amid ongoing market volatility.
Moderna Inc (NASDAQ:MRNA) saw its stock price drop by 7.75% in yesterday's trading session. This decline follows a period of uncertainty and volatility regarding the company's future prospects.
Advertisement
Moderna Inc
MRNA.US
MRNA.US
Moderna Inc
WealthAwesomeMarket cap
$78.65B
52W high
$212.22
52W low
$22.28
1W change
+4.27%
Beta
1.09
Analyst Price Targets
Based on 23 analysts covering MRNA · as of Oct 8, 2026
Wall Street analysts forecast MRNA stock price to fall 38.6% over the next 12 months.
Consensus
Hold3.17 / 5.00
Avg. Target
C$121.00
-38.6% Upside
Previously C$120.67 on Oct 5, 2026
Current Price
C$197.00
Last close
Analyst Breakdown (23 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on MRNA's historical volatility
30-Day Vol
74.5%
Annualized
90-Day Vol
194.0%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$235.52
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$209.08 | C$161.68 – C$270.38 |
| 60 trading days | C$221.91 | C$154.26 – C$319.21 |
| 90 trading days | C$235.52 | C$150.88 – C$367.63 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Keep an eye on market sentiment and developments in the biotech sector as Moderna faces challenges and opportunities after this recent performance.
7.75% Decline
Moderna's stock closed at CA$187.46, a notable decrease that raises concerns about investor confidence.
Bull case
Moderna has strong growth potential, especially with its advancements in mRNA technology and recent FDA approvals for updated vaccines, which could boost future revenue.
Bear case
The recent drop in stock price highlights worries about Moderna's reliance on COVID-19 vaccine sales and its struggle with profitability, leading to doubts about its long-term sustainability.
Market Context
Advertisement
The decline in Moderna's stock coincided with a broader market pullback, as U.S. stock futures pointed to a downward trend ahead of key economic data releases. Investors are being cautious, considering the potential impact of interest rate changes on growth stocks.
Investor Sentiment
The recent fall in Moderna's stock has prompted a reassessment of investor sentiment. After a period of optimism driven by vaccine developments, the market's shift may indicate growing concerns about the company's dependence on COVID-19 vaccine revenue and its profitability issues.
Looking Ahead
As Moderna navigates this downturn, analysts suggest that the company needs to show it can diversify its product offerings and improve profitability to regain investor confidence. Future developments in its pipeline and market conditions will be crucial in determining its stock performance.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
